finanzen.net
25.06.2019 16:47
Bewerten
(0)

Isofol Receives Clinical Use Patent Approval in the United States for Drug Candidate arfolitixorin

DRUCKEN

GOTHENBURG, Sweden, June 25, 2019 /PRNewswire/ -- Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced approval of a Clinical Use Patent for arfolitixorin in the United States. The patent expires in 2038 and is the second patent in a series of clinical patent applications for arfolitixorin to be granted. The patent covers a dose regimen for treating solid tumors, such as colorectal, stomach, breast and liver cancer.

The now granted patent, US 10,328,079, includes a dose regimen involving two or more injections of arfolitixorin in combination with 5-fluorouracil (5-FU). These two agents may also be given in combination with other anticancer drugs, such as oxaliplatin, irinotecan and bevacizumab.

Anders Rabbe, chief executive officer of Isofol, commented: "This patent, which has been applied worldwide, is a clinical patent based on data derived from a study of arfolitixorin and 5-FU in metastatic colorectal cancer patients. The data demonstrated superior activity of arfolitixorin and 5-FU compared to the standard of care therapy, leucovorin and 5 -FU. The patented dose regimen is closely related to the one used in our ongoing global pivotal Phase 3 study, AGENT, a multicenter study in patients with metastatic colorectal cancer".

For further information, please contact

Isofol Medical AB (publ)
Anders Rabbe, CEO
E­-mail: info@isofolmedical.com 
Phone: +46 (0)707 646 500

Investor Relations
LifeSci Advisors
Hans Herklots
E-mail: hherklots@lifesciadvisors.com
Phone: +41-79-598-7149

Media
LifeSci Public Relations
Alison Chen
E-mail: achen@lifescipublicrelations.com
Phone: +1-646-876-4932

Certified Adviser
FNCA Sweden AB
E-mail: info@fnca.se
Phone: +46-(0)-8-528-003-99

This information is information that Isofol Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 16:30 CET on June 25, 2019.

About arfolitixorin

Arfolitixorin is Isofol's proprietary drug candidate being developed to increase the efficacy of standard of care chemotherapy for advanced colorectal cancer. The drug candidate is currently being studied in a global Phase 3 clinical trial, AGENT. As the key active metabolite of the widely used folate-based drugs, arfolitixorin can potentially benefit all patients with advanced colorectal cancer, as it does not require complicated metabolic activation to become effective.

About Isofol Medical AB (publ)

Isofol Medical AB (publ) is a clinical stage biotech company developing arfolitixorin to improve the efficacy of standard of care chemotherapy for advanced colorectal cancer by increasing tumor response and progression free survival. Isofol holds a worldwide exclusive license agreement with Merck KGaA, Darmstadt, Germany to develop and commercialize arfolitixorin for oncology indications. Isofol Medical AB is traded on the Nasdaq First North Premier. Certified Adviser is FNCA Sweden AB.

www.isofolmedical.com 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/isofol-medical/r/isofol-receives-clinical-use-patent-approval-in-the-united-states-for-drug-candidate-arfolitixorin,c2848081

The following files are available for download:

https://mb.cision.com/Main/15598/2848081/1068444.pdf

PDF

Cision View original content:http://www.prnewswire.com/news-releases/isofol-receives-clinical-use-patent-approval-in-the-united-states-for-drug-candidate-arfolitixorin-300874440.html

SOURCE Isofol Medical

Anzeige
Anzeige
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Heute im Fokus

DAX beendet Handel höher -- US-Börsen mit leichtem Plus -- ams mit OSRAM-Gegenofferte -- Bayer-Strafe deutlich gesenkt -- Citigroup übertrifft Erwartungen -- Carl Zeiss Meditec, EVOTEC im Fokus

Moody's: BASF-Rating droht Herabstufung. Trump droht dem mit mauem Wachstum kämpfenden China mit neuen Zöllen. Milliardendeal zwischen Broadcom und Symantec angeblich geplatzt. OMV mit Millioneninvestition in Deutschland. Rheinmetall ergattert Großauftrag. Bitcoin rauscht unter 10.000 US-Dollar. Airbus-Aktie auf Rekordhoch.

Die 5 beliebtesten Top-Rankings

Promis
Diese Sternchen haben ihren eigenen Aktien-Index
Diese Aktien hat Warren Buffett im Depot
Die Änderungen unter den Top-Positionen
Die erfolgreichsten Kinofilme der letzten 25 Jahre
Welche Titel knackten die Milliardenmarke an den Kinokassen?
Das verdienen Aufsichtsratschefs in DAX-Konzernen
Deutlich unter Vorstandsgehältern
Apps & Social Media: Die wertvollsten Marken der Welt
Welche Marke macht das Rennen?
mehr Top Rankings

Umfrage

Wo sehen Sie den DAX Ende 2019?

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Wirecard AG747206
Deutsche Bank AG514000
Daimler AG710000
NEL ASAA0B733
Amazon906866
BayerBAY001
CommerzbankCBK100
BASFBASF11
Microsoft Corp.870747
Infineon AG623100
TeslaA1CX3T
Airbus SE (ex EADS)938914
Apple Inc.865985
EVOTEC SE566480
Deutsche Telekom AG555750